Survival Benefit of Chemotherapy According to 21-Gene Recurrence Score in Young Women with Breast Cancer.
A L NashY RenJ K PlichtaL H RosenbergerA M B van den BrueleM L DiNomeK WestbrookE Shelley HwangPublished in: Annals of surgical oncology (2023)
RS retains its prognostic value in younger patients with early stage HR-positive, HER2-negative breast cancer. Chemotherapy survival benefit was limited to patients aged 40-50 with pN1 disease and RS of 31-50. Therefore, chemotherapy decision-making should be especially preference-sensitive in women aged 40-50 with intermediate RS, where it may not provide a survival benefit for many women.
Keyphrases
- early stage
- free survival
- locally advanced
- end stage renal disease
- decision making
- polycystic ovary syndrome
- newly diagnosed
- chronic kidney disease
- peritoneal dialysis
- breast cancer risk
- pregnancy outcomes
- squamous cell carcinoma
- gene expression
- genome wide
- adipose tissue
- pregnant women
- skeletal muscle
- neoadjuvant chemotherapy
- sentinel lymph node
- patient reported
- genome wide analysis